Preticks
.
Follow Us
News Details
IMAC Holdings Receives FDA Authorization to Initiate Clinical Study of Its Umbilical Cord-Derived Allogenic Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
About IMAC Holdings, Inc.
NASDAQ: $IMAC
Notified: $1.84
11:58 EDT
Price Chart